How genomics reclassifies diseases : the case of Alport syndrome by Torra Balcells, Roser et al.
E D I T O R I A L C O M M E N T
How genomics reclassifies diseases: the case of Alport
syndrome
Roser Torra 1,2, Monica Furlano 1,2 and Elisabet Ars 3
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ABSTRACT
In this issue, Matthews et al. provide a comprehensive review of published cohorts with heterozygous pathogenic variants in
COL4A3 or COL4A4, documenting the wide spectrum of the disease. Due to the extreme phenotypes that patients with
heterozygous pathogenic variants in COL4A3 or COL4A4 may show, the disease has been referred to in a variety of ways,
including ‘autosomal dominant Alport syndrome’, ‘thin basement membrane disease’, ‘thin basement membrane
nephropathy’, ‘familial benign hematuria’ and ‘carriers of autosomal dominant Alport syndrome’. This confusion over
terminology has prevented nephrologists from being sufficiently aware of the relevance of the entity. Nowadays,
however, next-generation sequencing facilitates the diagnosis and it is becoming a relatively frequent finding in
haematuric–proteinuric nephropathies of unknown origin, even in non-familial cases. There is a need to raise awareness
among nephrologists about the disease in order to improve diagnosis and provide better management for these patients.
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It is well known that genomics can allow the reclassification of
genetic diseases, and inherited kidney diseases are no excep-
tion. Many renal diseases have been named after the physicians
who first identified them, as in the case of Fabry disease, von
Hippel–Lindau syndrome, Bartter syndrome and Liddle syn-
drome, among others. For some other diseases, a new name
more descriptive of the entity has generally replaced the origi-
nal name; examples include ‘tuberous sclerosis complex’ in-
stead of ‘Pringle-Bourneville disease’ and ‘immunoglobulin A
nephropathy’ instead of ‘Berger’s disease’. For nephropathies
caused by newly identified genes, the disease term frequently
originates from the gene itself plus a brief description of the
entity, such as autosomal dominant tubulointerstitial disease
(ADTKD) followed by the name of the causative gene, e.g.
ADTKD-UMOD (uromodulin) or ADTKD-MUC1 (mucin 1).
Giving descriptive names to new diseases is usually much
easier than changing old names in the light of new findings. In
the case of patients with heterozygous pathogenic variants in
COL4A3 or COL4A4, use of the traditional term Alport syndrome
is contentious, but a new term has yet to emerge. While Alport
syndrome as traditionally described fits very well into X-linked
(XLAS) and autosomal recessive (ARAS) forms, this does not
hold true for patients with heterozygous variants in COL4A3
or COL4A4. In this issue of CKJ, Matthews et al. provide a
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Editorial Comment
systematic review of published cases with heterozygous patho-
genic variants in COL4A3 or COL4A4. The terms ‘autosomal
dominant Alport syndrome’ (ADAS), ‘thin basement membrane
disease, ‘thin basement membrane nephropathy,’ ‘familial be-
nign hematuria’ and ‘carriers of ARAS’ have all been used to
designate this entity. This confusing terminology has prevented
many diagnoses and stopped many patients from receiving
early renin–angiotensin–aldosterone system inhibition, among
other measures. Also, the variation in names leads to bias in
published series, as patients are selected on the basis of the
presence of the clinical features associated with the name of
the disease specified in the individual article in question.
As shown in the review article by Matthews et al., carriers of
heterozygous pathogenic variants of COL4A3 or COL4A4 present
with a wide spectrum of clinical manifestations, ranging from
haematuria (or even bland urine sediment) to end-stage kidney
disease (ESKD) (Figure 1). Although two recent consensus docu-
ments have continued to use the term ‘thin basement mem-
brane disease’ [1, 2], this designation no longer seems suitable,
primarily because it is a pathological term and this finding can
be found in the early stages of XLAS and ARAS, as well as in
other glomerular diseases. For the same reason, focal segmental
glomerulosclerosis is not used for patients with heterozygous
pathogenic variants of COL4A3 or COL4A4 and advanced kidney
disease [3–5]. The name ‘familial benign hematuria’ is old fash-
ioned, as we now know that some of these patients may de-
velop ESKD, indicating that this is far from being a ‘benign’
disorder. Moreover, it makes little sense that different affected
members of a single family can be considered to have ‘different
diseases’ when all share the same single mutation, or that a sin-
gle patient may be given different names for his/her disease
over the course of his/her lifetime.
With all these terminological issues, Alport syndrome is at
least the second most common inherited kidney disease after
autosomal dominant polycystic kidney disease (ADPKD) [6]. It
may be even more prevalent than ADPKD if one takes into ac-
count the fact that many of these individuals show only micro-
haematuria. Of course, in terms of health impact, the most
relevant subgroup comprises individuals with heterozygous
pathogenic variants of COL4A3 or COL4A4 who develop ESKD.
Today there is a need for the nephrologist to be aware of the
existence of these diseases for many reasons: this will reduce
the number of patients with ‘nephropathy of unknown etiology’
who reach ESKD; it will allow genetic counselling and evalua-
tion of at-risk relatives; patients will be able to participate in
Alport syndrome clinical trials; early diagnosis will allow
patients to receive early antiproteinuric treatment, specific
treatment when available, and adequate follow-up; increased
knowledge of the disease will facilitate the development of
prognostic tools and therefore differentiation between those
patients who will progress to ESKD and those who will not; and
it will enable patients to get in touch with patient advocacy and
support groups.
The use of next-generation sequencing for routine analy-
ses of suspected cases of familial nephropathy is of seminal
relevance to the identification of ADAS patients who would
otherwise elude any diagnosis of kidney disease. But not only
family cases should be studied; expression of the disease is
highly variable in patients with heterozygous pathogenic var-
iants of COL4A3 or COL4A4, meaning that very extreme phe-
notypes may coexist within a single family. This may prevent
recognition of the fact that a genetic disease runs in the
family. Also, families may be unaware that relatives have
haematuria or chronic kidney disease, and even if they
are aware of it, the condition may have been attributed to age,
hypertension, diabetes, etc. Therefore ADAS should be
considered in the differential diagnosis of patients with
persistent glomerular haematuria, even without a family
history.
When nephrologists think of Alport syndrome, most will an-
ticipate some extrarenal manifestations, such as sensorineural
deafness and ocular anomalies, but, as shown by Matthews et
al., these findings are very uncommon in patients with hetero-
zygous pathogenic variants of COL4A3 or COL4A4.
The review by Matthews et al., and hopefully the future pub-
lication of findings in more cohorts, will raise awareness of this
‘not so rare’ disease and allow precise diagnosis and follow-up
for a significant number of kidney patients who have been
undiagnosed or misdiagnosed to date.
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FIGURE 1. Clinical spectrum of Alport syndrome according to the pattern of in-
heritance. Figure modified with permission from Nephrol Dial Transplant. 2019
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